Intellectual Property India Publishes Patent Application for 'Tetrahydroquinoline Derivatives For Inhibiting Cav3.2-Usp5 Interactions' Filed by Zymedyne Therapeutics Inc.

MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202517090706 A) filed by Zymedyne Therapeutics Inc., Calgary, Canada, on Sept. 23, for 'tetrahydroquinoline derivatives for inhibiting cav3.2-usp5 interactions.'

Inventor(s) include Patel, Ketulbhai; Derksen, Darren; and Zamponi, Gerald W.

The application for the patent was published on Oct. 10, under issue no. 41/2025.

According to the abstract released by the Intellectual Property India: "The present application relates to various uses of 5-membered cyclo-fused tetrahydroquinoline derivatives of Formula (I) in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions between Cav3.2 T-type calcium channels (Cav3.2) and ubiquitin specific peptidase 5 (USP5). For example, the compounds of Formula (I) are useful as an analgesic in the treatment of pain. The present application also relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof."

The patent application was internationally filed on Feb. 27, 2024, under International application No.PCT/CA2024/050243.

Disclaimer: Curated by HT Syndication.